FundaMental Pharma
From EverybodyWiki Bios & Wiki
FundaMental Pharma GmbH is a German biotechnology spin-off of Heidelberg University. It was founded in Heidelberg in 2016 with the goal to develop effective treatments for human neurodegenerative diseases. The founders of FundaMental Pharma discovered NMDAR/TRPM4 interaction interface inhibitors, also named ‘interface inhibitors’[1]. The first interface inhibitors are compound 8/Brophenexin and compound 19/Aliudanexin that are licensed to FundaMental Pharma.
References[edit]
- ↑ Yan, Jing; Bengtson, C. Peter; Buchthal, Bettina; Hagenston, Anna M.; Bading, Hilmar (9 October 2020). "Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants". Science. 370 (6513). doi:10.1126/science.aay3302. ISSN 1095-9203. PMID 33033186 Check
|pmid=value (help).
External links[edit]
This article "FundaMental Pharma" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:FundaMental Pharma. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
